Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.35 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.33 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8467567 | 0.86 | POLB (0.38) | TDP1APOBEC3GTAAR1HSPA5CA2 | |
| SCHEMBL5869932 | 0.84 | TAAR1 (0.35) | TAAR1HSPA5PKM | |
| SCHEMBL11261110 | 0.82 | LIPG (0.40) | TDP1CA2POLB | |
| SCHEMBL7942321 | 0.81 | TDP1 (0.36) | TDP1PTPN1FFAR1CA2 | |
| SCHEMBL31203 | 0.81 | TDP1 (0.55) | TDP1PTPN1APOBEC3GTAAR1HSPA5 | |
| SCHEMBL29534868 | 0.81 | TDP1 (0.55) | TDP1PTPN1APOBEC3GTAAR1HSPA5 | |
| SCHEMBL2808768 | 0.79 | TDP1 (0.34) | TDP1TSHRALDH1A1HTT | |
| SCHEMBL232082 | 0.79 | — | — | |
| SCHEMBL10719547 | 0.79 | LIPG (0.34) | TAAR1HSPA5 | |
| SCHEMBL1606781 | 0.77 | TAAR1 (0.31) | TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115817-A1 | PHTHALIMIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS AND/OR TNF-ALPHA MODULATORS, METHOD FOR PRODUCING SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USES THEREOF FOR THE TREATMENT OF INFLAMMATORY DISEASES | EMS S.A. (BR) | 2012-05-10 | — | — | US | claimed |
| EP-2418200-A1 | PHTHALIMIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS AND/OR TNF- MODULATORS, METHOD FOR PRODUCING SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USES THEREOF FOR THE TREATMENT OF INFLAMMATORY DISEASES | EMS S. A. (BR) | 2012-02-15 | — | — | EP | claimed |
| CN-101331133-A | Sulphonamidoaniline derivatives as Janus kinase inhibitors | NOVARTIS AG (CH) | 2008-12-24 | — | — | CN | claimed |
| US-20080261973-A1 | Sulphonamidoaniline Derivatives Being Janus Kinase Inhibitors | NOVARTIS AG (CH) | 2008-10-23 | — | — | US | claimed |
| EP-1966210-A2 | SULPHONAMIDOANILINE DERIVATIVES BEING JANUS KINASES INHIBITORS | Novartis AG (CH) | 2008-09-10 | — | — | EP | claimed |
| WO-2007071393-A2 | SULPHONAMIDOANILINE DERIVATIVES BEING JANUS KINASES INHIBITORS | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | claimed |
| US-20120167451-A1 | PYROLYSIS OIL BASED FUEL AND METHOD OF PRODUCTION | NEW GENERATION BIOFUELS HOLDINGS, INC. (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120115817-A1 | PHTHALIMIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS AND/OR TNF-ALPHA MODULATORS, METHOD FOR PRODUCING SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USES THEREOF FOR THE TREATMENT OF INFLAMMATORY DISEASES | EMS S.A. (BR) | 2012-05-10 | — | — | US | disclosed |
| EP-2418200-A1 | PHTHALIMIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS AND/OR TNF- MODULATORS, METHOD FOR PRODUCING SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USES THEREOF FOR THE TREATMENT OF INFLAMMATORY DISEASES | EMS S. A. (BR) | 2012-02-15 | — | — | EP | disclosed |
| WO-2012006316-A1 | PYROLYSIS OIL BASED FUEL AND METHOD OF PRODUCTION | NEW GENERATION BIOFUELS HOLDINGS, INC. (US) | 2012-01-12 | — | — | WO | disclosed |
| US-20100037513-A1 | Biofuel Composition and Method of Producing a Biofuel | NEW GENERATION BIOFUELS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| EP-2010631-A2 | BIOFUEL COMPOSITION AND METHOD OF PRODUCING A BIOFUEL | New Generation Biofuels, Inc. (US) | 2009-01-07 | — | — | EP | disclosed |
| CN-101331133-A | Sulphonamidoaniline derivatives as Janus kinase inhibitors | NOVARTIS AG (CH) | 2008-12-24 | — | — | CN | disclosed |
| US-20080261973-A1 | Sulphonamidoaniline Derivatives Being Janus Kinase Inhibitors | NOVARTIS AG (CH) | 2008-10-23 | — | — | US | disclosed |
| EP-1966210-A2 | SULPHONAMIDOANILINE DERIVATIVES BEING JANUS KINASES INHIBITORS | Novartis AG (CH) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007127059-A2 | BIOFUEL COMPOSITION AND METHOD OF PRODUCING A BIOFUEL | NEW GENERATION BIOFUELS, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007071393-A2 | SULPHONAMIDOANILINE DERIVATIVES BEING JANUS KINASES INHIBITORS | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
| US-6235067-B1 | LIQUID HYDROCARBON FUEL AND WATER SUPERCRITICAL MIXTURE EMITTER NOZZLES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2001-05-22 | — | — | US | disclosed |
| WO-1997003279-A9 | COMBUSTION OF NANOPARTITIONED FUEL | — | 1997-03-06 | — | — | WO | disclosed |
| WO-1997003279-A1 | COMBUSTION OF NANOPARTITIONED FUEL | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1997-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115817-A1 | PHTHALIMIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS AND/OR TNF-ALPHA MODULATORS, METHOD FOR PRODUCING SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USES THEREOF FOR THE TREATMENT OF INFLAMMATORY DISEASES | TNF, PER2, CRY1 | TDP1 4039/4885PTPN1 109/4885APOBEC3G 4863/4885 |
| US-20080261973-A1 | Sulphonamidoaniline Derivatives Being Janus Kinase Inhibitors | GRK4, JAK2, ALK | TDP1 4518/4885PTPN1 121/4885APOBEC3G 4833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.